Korean ultrasound manufacturer Medison will display a new ultrasound scanner at this week's AmericanInstitute of Ultrasound in Medicine conference that is easierto use than its previous ob/gyn product offering. Sonoace 5000is similar to Medison's Sonoace
Korean ultrasound manufacturer Medison will display a new ultrasound scanner at this week's AmericanInstitute of Ultrasound in Medicine conference that is easierto use than its previous ob/gyn product offering. Sonoace 5000is similar to Medison's Sonoace 1500 ob/gyn scanner, but addsimproved resolution, a larger monitor, and swivel and tilt capabilitiesto the monitor and keyboard for easier positioning, accordingto Mark Hayward, president of the company's U.S. subsidiary inPleasanton, CA.
Like Sonoace 1500, Sonoace 5000 is a gray-scale non-Dopplerscanner. Sonoace 5000's improved mechanical design makes it moresuited to ob/gyn studies with patients in the lithotomy position,Hayward said. While Sonoace 1500 is a tabletop unit, Sonoace 5000is a floor console system weighing about 140 pounds. Its 12-inchmonitor is also larger than that of the 1500.
List price of Sonoace 5000 is $30,950 and Medison is readyto begin shipping the scanner. Sonoace 1500 will remain in thecompany's product line, Hayward said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.